- Introducing From Symptoms to Signals
For decades, psychiatric research has been grounded in symptoms – what patients describe and what clinicians observe. Symptom checklists and interviews have been the foundation of diagnosis, treatment decisions, and the primary yardstick for measuring success in clinical trials.
We are now entering a new era. Advances in neuroscience and digital health mean we can move beyond symptoms alone, capturing objective signals from the brain and behaviour using biomarkers that provide measurble, real-time insights into mental health.
Our new blog, From Symptoms to Signals: A New Era in Psychiatry, provides a space for sharing ideas, science, and stories about the shift toward precision psychiatry.
In this first 8-part series we will explore the issues that have been top of our minds as we planned our upcoming clinical trial for MT1988, a novel treatment for cognitive impairment associated with schizophrenia. These include:
- How to make good on the promise of biomarkers in reshaping psychiatric drug development
- Why early stages of schizophrenia, and the clinical high-risk population, represents a critical window for intervention
- Why novel treatment approaches like MT1988 could make a real difference
- Behind the scenes of our work – from trial design to the people making it possible.
Follow our LinkedIn page to join the conversation and keep up with future posts under the From Symptoms to Signals banner.
Our first release date is: 13th October 2025.
We’d love to hear: what do you see as the most exciting opportunity in advancing precision psychiatry?
#FromSymptomstoSignals #PrecisionPsychiatry #Biomarkers #DrugDevelopment
